Skip to main content

Table 1 Clincopathological features of the study populations

From: Development of nomograms to predict axillary lymph node status in breast cancer patients

 

Training Cohort

Validation Cohort

N

%

N

%

Year Of Diagnosis

 2010

47,203

47.38

0

0.00

 2011

52,415

52.62

0

0.00

 2012

0

0.00

50,965

50.05

 2013

0

0.00

50,869

49.95

Age Group

 Age < =50Yrs

23,231

23.32

22,203

21.80

 50-60Yrs

25,967

26.07

26,600

26.12

  > 60Yrs

50,420

50.61

53,031

52.08

Location Of Lesions

 UIQ

18,891

18.96

19,939

19.58

 UOQ

53,372

53.58

54,995

54.00

 LOQ

11,425

11.47

11,776

11.56

 LIQ

9086

9.12

8776

8.62

 Central

6844

6.87

6348

6.23

Race

 White

84,246

84.57

85,967

84.42

 African American

10,334

10.37

10,429

10.24

 Others

4184

4.20

4568

4.49

 Unknown

854

0.86

870

0.85

T-Stage

 T1a

69,375

69.64

71,740

70.45

 T2

27,675

27.78

27,528

27.03

 T3

2568

2.58

2566

2.52

N-Stage

 N0

73,662

73.94

76,954

75.57

 N1

19,724

19.80

19,362

19.01

 N2

4313

4.33

3829

3.76

 N3

1919

1.93

1689

1.66

Histology

 IDC

75,974

76.27

77,806

76.40

 ILC

8582

8.61

9795

9.62

 IDC & ILC

5005

5.02

5076

4.98

 IDC & Others

3359

3.37

3390

3.33

 IMC

1849

1.86

1857

1.82

 Others

4849

4.87

3910

3.84

Grade

 I

25,663

25.76

26,780

26.30

 II

43,908

44.08

45,673

44.85

 III

29,420

29.53

28,304

27.79

 Others/NA

627

0.63

1077

1.06

Estrogen Receptor

 Negative

15,746

15.81

14,902

14.63

 Positive

83,872

84.19

86,932

85.37

Progesterone Receptor

 Negative

25,080

25.18

23,426

23.00

 Positive

74,538

74.82

78,408

77.00

Her2

 Negative

87,670

88.01

92,043

90.39

 Positive

11,948

11.99

9791

9.61

Lymphovascular Invasion

 Not Present

80,657

80.97

83,226

81.73

 Present

18,961

19.03

18,608

18.27

Charlson-Deyo Score

 0

83,641

83.96

84,466

82.94

 1

13,297

13.35

14,319

14.06

 2

2680

2.69

3049

2.99

Breast Surgery

 BCS + RT

64,552

64.80

66,480

65.28

 Mastectomyb

35,066

35.20

35,354

34.72

  1. NCDB national cancer database, Yrs years, HER2 human epidermal growth factor receptor 2, BCS breast-conserving surgery, RT radiotherapy, LIQ lower-inner quadrant, LOQ lower-outer quadrant, UIQ Upper-inner quadrant, UOQ Upper-outer quadrant, NA not available, IDC infiltrating ductal carcinoma, ILC infiltrating lobular carcinoma, IMC invasive mucinous carcinoma;
  2. aDCIS with micrometastasis (T1mic) were included in T1
  3. bSubcutaneous mastectomy and reconstruction surgery were included